NasdaqGM - Delayed Quote USD

TriSalus Life Sciences, Inc. (TLSIW)

Compare
1.1200
+0.0200
+(1.82%)
At close: January 30 at 4:00:00 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Mary T. Szela B.S.N., M.B.A. CEO, President & Director 880.67k -- 1963
Mr. Sean Edward Murphy CFO & Director 628.75k -- 1953
Ms. Lori Ann Santamaria Vice President of Operations -- -- --
Dr. Bryan F. Cox Ph.D. Chief Scientific & Manufacturing Officer -- -- 1962
Mr. James E. Young Senior VP of Investor Relations & Treasurer -- -- --
Dr. Richard B. Marshak M.B.A., MBA, VMD Senior Vice President of Corporate Development & Strategy -- -- 1959
Ms. Jennifer L. Stevens J.D. Chief Regulatory Officer 630k -- 1962
Ms. Jodi Devlin President of Commercial Operations -- -- 1963

TriSalus Life Sciences, Inc.

6272 West 91st Avenue
Westminster, CO 80031
United States
303 442 1222 https://trisaluslifesci.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
107

Description

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Corporate Governance

TriSalus Life Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events